Literature DB >> 26259961

Trace levels of the CHO host cell protease cathepsin D caused particle formation in a monoclonal antibody product.

Jared S Bee1, Liu Tie1, Douglas Johnson1, Mariana N Dimitrova1, Kristin C Jusino2, Christopher D Afdahl2.   

Abstract

Chinese hamster ovary (CHO) cells are often used to produce therapeutic monoclonal antibodies (mAbs). CHO cells express many host cell proteins (HCPs) required for their growth. Interactions of HCPs with mAbs can sometimes result in co-purification of trace levels of 'hitchhiker' HCPs during the manufacturing process. Purified mAb-1 product produced in early stages of process optimization had high HCP levels. In addition, these lots formed delayed-onset particles containing mAb-1 and its heavy chain C-terminal fragments. Studies were performed to determine the cause of the observed particle formation and to optimize the purification for improved HCP clearance. Protease activity and inhibitor stability studies confirmed that an aspartyl protease was responsible for fragmentation of mAb-1 resulting in particle formation. An affinity resin was used to selectively capture aspartyl proteases from the mAb-1 product. Mass spectrometry identified the captured aspartyl protease as CHO cathepsin D. A wash step at high pH with salt and caprylate was implemented during the protein A affinity step to disrupt the HCP-mAb interactions and improve HCP clearance. The product at the end of purification using the optimized process had very low HCP levels, did not contain detectable protease activity, and did not form particles. Spiking of CHO cathepsin D back into mAb-1 product from the optimized process confirmed that it was the cause of the particle formation. This work demonstrated that process optimization focused on removal of HCPs was successful in eliminating particle formation in the final mAb-1 product.
© 2015 American Institute of Chemical Engineers.

Entities:  

Keywords:  cathepsin D; host-cell protein; monoclonal antibody; particles; purification

Mesh:

Substances:

Year:  2015        PMID: 26259961     DOI: 10.1002/btpr.2150

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  11 in total

1.  Identification and CRISPR/Cas9 Inactivation of the C1s Protease Responsible for Proteolysis of Recombinant Proteins Produced in CHO Cells.

Authors:  Sophia W Li; Bin Yu; Gabriel Byrne; Meredith Wright; Sara O'Rourke; Kathryn Mesa; Phillip W Berman
Journal:  Biotechnol Bioeng       Date:  2019-06-10       Impact factor: 4.530

2.  Effects of lysosomal biotherapeutic recombinant protein expression on cell stress and protease and general host cell protein release in Chinese hamster ovary cells.

Authors:  Damiano Migani; C Mark Smales; Daniel G Bracewell
Journal:  Biotechnol Prog       Date:  2017-03-29

3.  Proteomic Analysis of Host Cell Protein Dynamics in the Culture Supernatants of Antibody-Producing CHO Cells.

Authors:  Jin Hyoung Park; Jong Hwa Jin; Myung Sin Lim; Hyun Joo An; Jong Won Kim; Gyun Min Lee
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

4.  Cathepsin L Causes Proteolytic Cleavage of Chinese-Hamster-Ovary Cell Expressed Proteins During Processing and Storage: Identification, Characterization, and Mitigation.

Authors:  Haibin Luo; Liu Tie; Mingyan Cao; Alan K Hunter; Timothy M Pabst; Jiali Du; Raymond Field; Yuling Li; William K Wang
Journal:  Biotechnol Prog       Date:  2018-11-04

5.  Multiplex secretome engineering enhances recombinant protein production and purity.

Authors:  Stefan Kol; Daniel Ley; Tune Wulff; Marianne Decker; Johnny Arnsdorf; Sanne Schoffelen; Anders Holmgaard Hansen; Tanja Lyholm Jensen; Jahir M Gutierrez; Austin W T Chiang; Helen O Masson; Bernhard O Palsson; Bjørn G Voldborg; Lasse Ebdrup Pedersen; Helene Faustrup Kildegaard; Gyun Min Lee; Nathan E Lewis
Journal:  Nat Commun       Date:  2020-04-20       Impact factor: 14.919

6.  Identification and characterization of a residual host cell protein hexosaminidase B associated with N-glycan degradation during the stability study of a therapeutic recombinant monoclonal antibody product.

Authors:  Xuanwen Li; Yan An; Jing Liao; Li Xiao; Michael Swanson; Kirby Martinez-Fonts; Jorge Alexander Pavon; Edward C Sherer; Vibha Jawa; Fengqiang Wang; Xinliu Gao; Simon Letarte; Douglas D Richardson
Journal:  Biotechnol Prog       Date:  2021-03-12

7.  Quantitative definition and monitoring of the host cell protein proteome using iTRAQ - a study of an industrial mAb producing CHO-S cell line.

Authors:  Lesley M Chiverton; Caroline Evans; Jagroop Pandhal; Andrew R Landels; Byron J Rees; Peter R Levison; Phillip C Wright; C Mark Smales
Journal:  Biotechnol J       Date:  2016-06-22       Impact factor: 4.677

8.  Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry.

Authors:  Florian Füssl; Anne Trappe; Ken Cook; Kai Scheffler; Oliver Fitzgerald; Jonathan Bones
Journal:  MAbs       Date:  2018-11-11       Impact factor: 5.857

9.  Improving the analytical toolbox to investigate copurifying host cell proteins presence: N-(4)-(β-acetylglucosaminyl)- l-asparaginase case study.

Authors:  Séverine Clavier; Delphine Fougeron; Suzana Petrovic; Hagit Elmaleh; Céline Fourneaux; Dawid Bugnazet; Francis Duffieux; Alessandro Masiero; Shibani Mitra-Kaushik; Bruno Genet; Yann Fromentin; Patrick Kreiss; Bénédicte Laborderie; Dominique Brault; Jean-Michel Menet
Journal:  Biotechnol Bioeng       Date:  2020-08-03       Impact factor: 4.395

10.  Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development.

Authors:  Rosalynn Molden; Mengqi Hu; Sook Yen E; Diana Saggese; James Reilly; John Mattila; Haibo Qiu; Gang Chen; Hanne Bak; Ning Li
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.